Evidence map›Paper›PMID 40004003›Full record

ArticleInternational journal of molecular sciences2025

Novel Method for the Synthesis of Hydroxycobalamin[

Zuzanna Rzepka, Magdalena Janus, Krzysztof Marciniec, Jakub Rok, Dorota Wrześniok

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zuzanna RzepkaDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska, 41-200 Sosnowiec, Poland.ORCID 0000-0001-7892-0462
Magdalena JanusDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska, 41-200 Sosnowiec, Poland.
Krzysztof MarciniecDepartment of Organic Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska, 41-200 Sosnowiec, Poland.ORCID 0000-0003-4631-2360
Jakub RokDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska, 41-200 Sosnowiec, Poland.ORCID 0000-0002-8260-4339
Dorota WrześniokDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 4 Jagiellońska, 41-200 Sosnowiec, Poland.ORCID 0000-0002-6918-3330

Funding

Medical University of Silesia BNW-1-013/N/3/FMedical University of Silesia BNW-1-037/N/4/FMedical University of Silesia BNW-2-038/K/4/F
6 · The paper itself

Abstract

The ability to over-proliferate is a hallmark of cancer cells, so inhibiting proliferation is crucial for successful cancer treatment. Vitamin B12 (cobalamin) is among the factors necessary for replication of genetic material and cell division. There is currently no cobalamin antagonist with therapeutic use. Nevertheless, the idea of inhibiting cobalamin-dependent metabolic pathways as a potential anticancer strategy is of interest to many researchers. In this study, we investigated, for the first time, the impact of cobalamin deficiency on melanoma cells' growth. To achieve a cobalamin-deficient state in cellulo, hydroxycobalamin[

Indexed as

Antineoplastic AgentsMelanomaVitamin B 12Cell Line, TumorCell ProliferationHumansAntineoplastic AgentsVitamin B 12antivitamin B12cobalamincobalamin deficiencyhydroxycobalamin[c-lactam]melanoma

Identifiers

PMID40004003
PMCPMC11855847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.